Core tests®
Prevent the spread of respiratory viruses this winter with a unique 4-in-1 LFT. The new Core Tests® ComboResp Lateral Flow Test is a government approved lateral flow test allowing you to detect and specify COVID, Influenza A, Influenza B and RSV from a single swab.
The key to viral respiratory infection prevention and management in care settings is to detect infections early. The earlier you can spot the infection, the earlier you can act to protect both staff and patients. With the Core Tests® ComboResp lateral flow tests you can take control by testing for the four key infectious respiratory viruses at once with just one single nasal swab. Protect your staff, protect your residents, protect your business.
Key Features:
- Rapid - Test time of just 10 minutes
- Reliable - CTDA approved and CE-IVD marked
- Convenient - 1 swab, 1 test card, 4 results - patient friendly
- User-friendly - familiar standard lateral flow procedure
Diagnostic Sensitivity and Specificity:
- Influenza A: Sensitivity of 99.2% (118/119), Specificity of 99.6% (479/481), Total Agreement of 99.5% (597/600).
- Influenza B: Sensitivity of 99.1% (109/110), Specificity of 99.8% (489/490), Total Agreement of 99.7% (598/600).
- Covid-19: Sensitivity of Samples with PCR CT < 25 was 100% (n = 110), overall 70.91% (78/110), Specificity: 100.00% (150/150), Total Agreement: of 87.69% (228/260).
- RSV: Sensitivity of 97.4% (112/115), Specificity of 99.3% (298/300), Total Agreement of 98.8% (410/415).
CE ISO 9001, ISO 13485 Certified
Available as a single test pack or a pack of 25 tests:
CLH Code: 903248 - Single Test Pack Contents:
- 1 Test Cassette
- 1 Sample Collection Tube with Processing Solution
- 1 Sampling Swab
- 1 Instructions for use
CLH Code: 903243-C - 25 Test Packs Contents:
- 1 Test Cassette
- 1 Sample Collection Tube with Processing Solution
- 1 Sampling Swab
- 1 Instructions for use
The recent emergence of COVID-19 variant BA 2.86 has led some people to ask if they should reassess their behaviour in response or indeed to any other new variants of concern. As we brace ourselves for chillier days, more indoor gatherings and seasonal social events with friends and family, it is timeous to revive behaviours that can reduce the spread of COVID-19 and other respiratory infections known to peak during the autumn and winter period.
In any institutional situation like a care-home or hospital, if you have an outbreak of a respiratory virus for example, this could become a significant event, particularly if you have any pre-disposed personnel/patients or are classed as a vulnerable person. The number of Acute Respiratory Incidents reported in England in the 2022/23 winter season amounted to 6,049 in closed settings. Of these, 5,006 (82.8%) were reported from care homes (see full report at https://www.gov.uk). This portrays the very real challenge to a care home that these winter infections represent in order to fulfil a duty of care to patients and also minimise hospitalisations and the pressure this creates every winter on the NHS.
This new 4 in 1 diagnostic tool is for professionals to add to their defences this winter in the form of a rapid (10 minute) lateral flow test which will differentiate Flu-A/Flu-B/ SARS-Cov-2/RSV all with just one swab. This test is CTDA approved and MHRA registered and suitable for use within your care home or at the point-of-care. Should you be considering this 4 in 1 lateral flow test product for your patients or staff this winter?
